Clinical Trials Browser

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07440290 2026-02-27

DETERMINE

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

Clinical Trials

VEN+IDAC vs IDAC in AML

DETERMINE

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

GRAALL-2024

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

FORUM2

Mature B-Cell Lymphoma And Leukemia Study III

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

DETERMINE

DETERMINE

DETERMINE

DETERMINE

DETERMINE

DETERMINE

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

CCCG-TALL-2025

CCCG-LR-B-ALL

Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL

Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

CCCG-I/HR-ALL

WT1 for the Detection of Minimal Residual Disease

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Ven APL

Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors

RATIONALISE

VA vs DA for Newly Diagnosed Hig-risk AML

Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult

ALFA1401

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

SCCLG-M5

COSI

VHA

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT

GLOBAL

Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission